Cefotaxim MIP: Uses, Dosage & Side Effects
A third-generation cephalosporin antibiotic for serious bacterial infections, administered by injection or infusion in hospital settings
Cefotaxim MIP contains the active substance cefotaxime, a third-generation cephalosporin antibiotic used to treat serious bacterial infections. It belongs to the beta-lactam class of antibiotics and works by disrupting bacterial cell wall synthesis, leading to cell death. Cefotaxim MIP is listed on the WHO Model List of Essential Medicines and is widely used worldwide for infections including bacterial meningitis, pneumonia, septicemia, urinary tract infections, and intra-abdominal infections. It is administered by injection or infusion in hospital settings and requires a prescription. Cefotaxime is valued for its broad spectrum of activity against Gram-positive and Gram-negative bacteria, excellent tissue penetration, and ability to reach therapeutic concentrations in the cerebrospinal fluid.
Quick Facts: Cefotaxim MIP
Key Takeaways
- Cefotaxim MIP (cefotaxime) is a third-generation cephalosporin antibiotic on the WHO Essential Medicines List, used to treat serious bacterial infections including meningitis, septicemia, pneumonia, and complicated urinary tract infections.
- It is administered exclusively by injection (intravenous or intramuscular) in hospital or clinical settings and is not available as an oral formulation; typical treatment courses range from 5 days to several weeks depending on the infection type.
- Patients with a known allergy to cephalosporins must not receive Cefotaxim MIP, and those with penicillin allergy should be treated with caution due to cross-reactivity risk of approximately 1–10%.
- The most common side effects are injection site reactions, diarrhea, and skin rashes; serious but rare adverse effects include anaphylaxis, Clostridioides difficile-associated diarrhea, and blood disorders.
- Cefotaxime penetrates the blood-brain barrier when meninges are inflamed, making it a first-line choice for empirical treatment of bacterial meningitis in neonates, children, and adults.
What Is Cefotaxim MIP and What Is It Used For?
Cefotaxim MIP contains cefotaxime sodium, a semisynthetic, broad-spectrum cephalosporin antibiotic that belongs to the third generation of this drug class. Cephalosporins are a subgroup of beta-lactam antibiotics, named after the beta-lactam ring in their molecular structure that is essential for their antibacterial activity. Third-generation cephalosporins like cefotaxime were developed in the late 1970s and early 1980s to provide enhanced activity against Gram-negative bacteria while retaining meaningful activity against Gram-positive organisms. Since its introduction, cefotaxime has become one of the most widely prescribed parenteral antibiotics in hospital medicine worldwide.
The antibacterial mechanism of cefotaxime involves inhibition of bacterial cell wall synthesis. Specifically, cefotaxime binds to penicillin-binding proteins (PBPs), which are transpeptidase enzymes that catalyze the final cross-linking step in peptidoglycan biosynthesis. Peptidoglycan is the structural polymer that gives bacterial cell walls their rigidity and strength. When cefotaxime binds to PBPs (particularly PBP 1a, PBP 1b, and PBP 3), it prevents the cross-linking of peptidoglycan strands, resulting in a weakened cell wall. The bacterium then undergoes osmotic lysis and dies. This mechanism makes cefotaxime bactericidal rather than merely bacteriostatic, meaning it actively kills bacteria rather than just inhibiting their growth.
A key advantage of cefotaxime over earlier cephalosporin generations is its enhanced stability against hydrolysis by many beta-lactamases, the enzymes that bacteria produce to inactivate beta-lactam antibiotics. While first-generation cephalosporins (such as cefazolin) are readily destroyed by many beta-lactamases, cefotaxime has a structural configuration that makes it resistant to a wider range of these enzymes. However, it is important to note that cefotaxime is not active against bacteria that produce extended-spectrum beta-lactamases (ESBLs) or AmpC-type beta-lactamases, which represents an important limitation in the era of increasing antimicrobial resistance.
Cefotaxime has a broad spectrum of antibacterial activity. It is effective against many Gram-positive bacteria including Streptococcus pneumoniae (including many penicillin-intermediate strains), Streptococcus pyogenes, and Staphylococcus aureus (methicillin-susceptible strains only). Its Gram-negative coverage includes Escherichia coli, Klebsiella species, Proteus mirabilis, Haemophilus influenzae (including beta-lactamase producers), Neisseria meningitidis, Neisseria gonorrhoeae, and many Enterobacter species. It is also active against most anaerobes except Bacteroides fragilis. Notably, cefotaxime has no clinically useful activity against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species, Listeria monocytogenes, or Pseudomonas aeruginosa.
Cefotaxim MIP is indicated for the treatment of the following infections when caused by susceptible organisms:
- Bacterial meningitis: Cefotaxime is a first-line empirical treatment for community-acquired bacterial meningitis in neonates, children, and adults. Its excellent penetration into the cerebrospinal fluid (CSF) when meninges are inflamed makes it particularly valuable for this life-threatening condition. It covers the most common causative agents including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.
- Septicemia (bloodstream infections): Cefotaxime is used for empirical and targeted treatment of bacteremia and sepsis caused by susceptible Gram-positive and Gram-negative organisms.
- Lower respiratory tract infections: Including community-acquired pneumonia, hospital-acquired pneumonia (when caused by susceptible pathogens), lung abscess, and empyema.
- Complicated urinary tract infections: Including pyelonephritis (kidney infection) and complicated cystitis requiring parenteral antibiotic therapy.
- Intra-abdominal infections: Including peritonitis, biliary tract infections, and intra-abdominal abscess, often used in combination with an agent active against anaerobes such as metronidazole.
- Bone and joint infections: Including osteomyelitis and septic arthritis caused by susceptible organisms.
- Skin and soft tissue infections: Including cellulitis, wound infections, and necrotizing soft tissue infections when caused by susceptible bacteria.
- Gonorrhea: Cefotaxime is an alternative treatment for uncomplicated and disseminated gonococcal infections.
- Surgical prophylaxis: Cefotaxime is used as perioperative prophylaxis to prevent infections in certain surgical procedures, particularly gastrointestinal, gynecological, and urological operations.
Cefotaxime is included on the World Health Organization Model List of Essential Medicines, recognizing its importance as a critical antibiotic for healthcare systems worldwide. It is listed among the core antibiotics needed for managing serious infections, particularly bacterial meningitis and neonatal sepsis, in both resource-limited and high-income settings.
What Should You Know Before Receiving Cefotaxim MIP?
Contraindications
There are specific situations in which Cefotaxim MIP must not be used. Understanding these absolute contraindications is essential before treatment begins.
- Hypersensitivity to cefotaxime: Do not receive Cefotaxim MIP if you have ever had a severe allergic reaction (including anaphylaxis) to cefotaxime or to any other cephalosporin antibiotic. Even mild previous reactions to cephalosporins should be reported to your doctor.
- Severe hypersensitivity to other beta-lactam antibiotics: Patients who have experienced a severe, immediate (Type I) hypersensitivity reaction to any beta-lactam antibiotic (including penicillins, carbapenems, or monobactams) should generally not receive cephalosporins unless the benefit clearly outweighs the risk and appropriate monitoring is in place.
- Hypersensitivity to lidocaine (for IM use only): When cefotaxime is reconstituted with lidocaine for intramuscular injection to reduce pain, it must not be given to patients with known allergy to lidocaine or other local anesthetics of the amide type, and it must not be administered intravenously.
Warnings and Precautions
Serious and occasionally fatal anaphylactic reactions have been reported in patients receiving cephalosporin antibiotics including cefotaxime. If an allergic reaction occurs during administration, stop the infusion immediately and initiate emergency treatment. Resuscitation equipment and epinephrine (adrenaline) should always be available when administering parenteral cephalosporins.
Before and during treatment with Cefotaxim MIP, your doctor should be informed if any of the following apply:
- Penicillin allergy: Cross-reactivity between penicillins and cephalosporins occurs in approximately 1–10% of patients. If you have a penicillin allergy, particularly a non-severe delayed reaction, your doctor may decide that cefotaxime can be used with caution. However, patients with a history of severe immediate-type (anaphylactic) reaction to penicillin should generally avoid cephalosporins.
- Renal impairment: Cefotaxime and its active metabolite desacetylcefotaxime are primarily excreted by the kidneys. In patients with significant renal impairment (creatinine clearance below 10 mL/min), dose reduction is necessary to prevent drug accumulation and potential toxicity, including neurotoxicity manifesting as encephalopathy, myoclonus, and seizures.
- Hepatic impairment: While cefotaxime is partially metabolized in the liver, dose adjustments for mild-to-moderate liver disease are usually not required. However, monitoring of liver function during prolonged treatment is recommended.
- History of gastrointestinal disease: Particularly a history of colitis. All antibiotics, including cefotaxime, can cause Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis. If significant diarrhea develops during or after treatment, CDAD should be considered.
- Sodium content: Each gram of cefotaxime sodium contains approximately 2.09 mmol (48.2 mg) of sodium. This should be taken into account for patients on a sodium-restricted diet, particularly when high doses are administered.
- Superinfection: Prolonged use of cefotaxime may result in overgrowth of non-susceptible organisms, including fungi (Candida species) and resistant bacteria. Regular monitoring and appropriate measures should be taken if superinfection occurs.
- Laboratory test interference: Cefotaxime may cause a false-positive result in Coombs' test (direct antiglobulin test) and in urine glucose tests that use non-enzymatic (copper reduction) methods. Enzymatic glucose oxidase methods should be used instead.
Pregnancy and Breastfeeding
Cefotaxime crosses the placental barrier and reaches the fetal circulation. Animal studies have not demonstrated teratogenic effects (birth defects), and limited clinical data in pregnant women have not revealed increased risk of congenital abnormalities. However, as with all medications during pregnancy, Cefotaxim MIP should only be used when the expected benefit to the mother clearly justifies the potential risk to the fetus. Your doctor will make this assessment based on the severity of the infection and the available treatment alternatives.
Cefotaxime is excreted in breast milk in low concentrations (approximately 0.3 mcg/mL following a 1 g dose). While the amounts are generally considered too small to cause direct toxicity in the nursing infant, there are theoretical risks including sensitization to cephalosporins, disruption of the infant’s intestinal flora, and interference with the interpretation of culture results if the infant needs investigation for infection. The decision to continue or discontinue breastfeeding during cefotaxime treatment should be made in consultation with your doctor, considering the importance of the antibiotic to the mother.
Cefotaxime has not been shown to impair fertility in animal studies. There are no data suggesting effects on human fertility.
Cefotaxime should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Inappropriate use of antibiotics contributes to the development of antimicrobial resistance, which is recognized by the WHO as one of the greatest threats to global health. Your doctor will carefully consider whether cefotaxime is the most appropriate antibiotic for your specific infection.
How Does Cefotaxim MIP Interact with Other Drugs?
Drug interactions can change how a medication works or increase the risk of serious side effects. Although Cefotaxim MIP has fewer clinically significant drug interactions than some other antibiotic classes, several important interactions should be considered. Always inform your doctor about all medicines you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Probenecid | Inhibits renal tubular secretion of cefotaxime, increasing plasma concentrations and prolonging half-life | Dose adjustment may be needed; monitor for increased side effects |
| Aminoglycosides (gentamicin, tobramycin, amikacin) | Synergistic antibacterial activity but additive nephrotoxicity risk | Monitor renal function closely; do not mix in the same infusion container as they are physically incompatible |
| Loop diuretics (furosemide, bumetanide) | May increase risk of nephrotoxicity through additive effects on the kidney | Monitor renal function and electrolytes during concurrent use |
| Oral anticoagulants (warfarin) | Cephalosporins may enhance the anticoagulant effect by suppressing vitamin K-producing gut flora | Monitor INR more frequently; dose adjustment of anticoagulant may be needed |
Minor Interactions and Precautions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Hormonal contraceptives | Antibiotics may theoretically reduce efficacy of oral contraceptives by disrupting enterohepatic circulation of estrogens | Consider additional barrier contraception during treatment; clinical significance debated |
| Bacteriostatic antibiotics (tetracyclines, chloramphenicol) | Theoretical antagonism: bacteriostatic agents may reduce the bactericidal activity of cefotaxime | Avoid concurrent use when possible; combination rarely indicated |
| Methotrexate | Cephalosporins may reduce renal clearance of methotrexate, increasing risk of toxicity | Monitor methotrexate levels and renal function if concurrent use is unavoidable |
| Alcohol | Unlike some cephalosporins (cefoperazone, cefamandole), cefotaxime does not cause a disulfiram-like reaction with alcohol | No specific alcohol restriction, though alcohol should generally be avoided during acute illness |
Cefotaxim MIP solution must not be mixed with aminoglycoside antibiotics in the same syringe or infusion container, as they are physically and chemically incompatible. If both drugs are prescribed, they must be administered separately through different IV lines or at different times. Additionally, cefotaxime should not be mixed with alkaline solutions (such as sodium bicarbonate) as this may accelerate degradation of the antibiotic.
What Is the Correct Dosage of Cefotaxim MIP?
The dose of Cefotaxim MIP depends on the type and severity of infection, the susceptibility of the causative organism, the patient’s age, body weight, and renal function. Treatment should ideally be guided by culture and sensitivity results, but empirical therapy is often initiated before results are available. All doses refer to cefotaxime base. The following dosage recommendations are based on international guidelines and the approved product information.
Adults
Standard Adult Dosing
| Infection Type | Dose | Frequency | Maximum Daily Dose |
|---|---|---|---|
| Uncomplicated infections | 1 g | Every 12 hours | 2 g/day |
| Moderate infections | 1–2 g | Every 8 hours | 6 g/day |
| Severe or life-threatening infections | 2 g | Every 6–8 hours | 12 g/day |
| Bacterial meningitis | 2 g | Every 6 hours (or 3 g every 8 hours) | 12 g/day |
| Uncomplicated gonorrhea | 500 mg | Single dose (IM) | 500 mg (single dose) |
| Surgical prophylaxis | 1–2 g | Single dose 30–60 min before incision | 2 g (may repeat if surgery prolonged) |
Children
Dosing in children is based on body weight. The recommended dose depends on the severity of the infection and the child’s age. Neonates require special consideration due to their immature renal function.
Pediatric Dosing
| Age Group | Standard Dose | Severe Infections / Meningitis | Frequency |
|---|---|---|---|
| Premature neonates | 50 mg/kg/day | 50 mg/kg/day | Divided into 2 doses (every 12 hours) |
| Neonates (0–28 days) | 50–100 mg/kg/day | 150–200 mg/kg/day | Divided into 2–3 doses |
| Infants and children (1 month–12 years) | 100–150 mg/kg/day | 200–300 mg/kg/day | Divided into 3–4 doses (every 6–8 hours) |
| Children >12 years / >50 kg | Adult dosing | Adult dosing | As per adult regimen |
Elderly
In elderly patients with normal renal function, no dose adjustment is typically required. However, elderly patients are more likely to have reduced renal function, and dose adjustment based on creatinine clearance should be considered. Renal function should be monitored during treatment, particularly when high doses are used or when treatment is prolonged. The pharmacokinetics of cefotaxime may be altered in elderly patients due to age-related decreases in renal blood flow and glomerular filtration rate.
Renal Impairment
In patients with severe renal impairment (creatinine clearance below 10 mL/min), the maintenance dose should be halved while keeping the same dosing interval, or the dosing interval should be doubled while maintaining the same dose. This is because cefotaxime and its active metabolite desacetylcefotaxime are primarily eliminated by the kidneys. In patients undergoing hemodialysis, a supplementary dose should be given after each dialysis session, as cefotaxime is partially removed by dialysis.
Missed Dose
Since Cefotaxim MIP is administered by healthcare professionals in hospital settings, missed doses are uncommon. However, if a dose is missed, it should be given as soon as possible. If it is nearly time for the next scheduled dose, the missed dose should be skipped—do not double the next dose to make up for the one that was missed. The treating physician should be informed of any missed doses so that the treatment plan can be adjusted if necessary. Maintaining consistent drug levels is important for effective bacterial eradication and for preventing the emergence of resistant organisms.
Overdose
Overdose with cefotaxime is uncommon in clinical practice but may occur, particularly in patients with impaired renal function. Signs and symptoms of overdose may include nausea, vomiting, diarrhea, and neurological manifestations such as encephalopathy (confusion, altered consciousness), myoclonus (involuntary muscle jerks), and seizures. High CSF concentrations of beta-lactam antibiotics are associated with neurotoxicity.
There is no specific antidote for cefotaxime overdose. Treatment is supportive and symptomatic. In cases of severe overdose, particularly in patients with renal failure, hemodialysis may be considered to enhance drug elimination, although data on the efficacy of dialysis in cefotaxime overdose are limited. Seizures should be managed with benzodiazepines (such as diazepam or lorazepam) according to standard protocols.
For intravenous injection, reconstitute 1 g of cefotaxime with 4 mL of Water for Injections and inject slowly over 3–5 minutes. For intravenous infusion, reconstitute the powder and further dilute in a compatible infusion fluid (0.9% sodium chloride or 5% glucose) and administer over 20–60 minutes. For intramuscular injection, reconstitute with Water for Injections or lidocaine solution and inject deeply into a large muscle mass (such as the gluteus maximus). Intramuscular injections should not exceed 1 g per injection site.
What Are the Side Effects of Cefotaxim MIP?
Like all medicines, Cefotaxim MIP can cause side effects, although not everybody gets them. Most side effects are mild to moderate and resolve after treatment is completed. However, some serious adverse reactions can occur, and it is important to recognize them early. Tell your healthcare provider immediately if you experience any unusual symptoms during or after treatment.
Side effects are classified by frequency according to the following convention: very common (affects more than 1 in 10 patients), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (1 in 1,000 to 1 in 10,000), and very rare or not known (fewer than 1 in 10,000 or frequency cannot be estimated from available data).
Common
Affects 1 to 10 in every 100 patients
- Injection site reactions: pain, induration (hardness), and inflammation at the injection site
- Thrombophlebitis (inflammation of the vein) following intravenous administration
- Diarrhea
- Nausea and vomiting
- Skin rash, urticaria (hives), and pruritus (itching)
- Transient elevation of liver enzymes (AST, ALT, gamma-GT)
- Transient elevation of blood urea and creatinine
- Eosinophilia (increased eosinophil white blood cells)
- Fever
Uncommon
Affects 1 to 10 in every 1,000 patients
- Clostridioides difficile-associated diarrhea and pseudomembranous colitis
- Neutropenia (decreased white blood cells)
- Thrombocytopenia (decreased platelets)
- Leukopenia (decreased white blood cell count)
- Headache
- Dizziness
- Candida superinfection (oral thrush, vaginal candidiasis)
- Elevated bilirubin
Rare
Affects 1 to 10 in every 10,000 patients
- Anaphylaxis and anaphylactoid reactions (severe allergic reactions with breathing difficulty, hypotension, facial/throat swelling)
- Stevens-Johnson syndrome and toxic epidermal necrolysis (severe skin reactions with widespread blistering)
- Erythema multiforme (target-shaped skin lesions)
- Seizures and encephalopathy (particularly with high doses in patients with renal impairment)
- Hemolytic anemia (destruction of red blood cells)
- Agranulocytosis (severe reduction in white blood cells)
- Interstitial nephritis (kidney inflammation)
- Cardiac arrhythmias following rapid IV bolus injection via central venous catheter
Not Known
Frequency cannot be estimated from available data
- Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)
- Acute generalized exanthematous pustulosis (AGEP)
- Jarisch-Herxheimer reaction (when treating spirochetal infections)
- Positive Coombs' test (without clinical hemolysis)
- Prolonged prothrombin time
Stop treatment and contact your doctor or go to the nearest emergency department immediately if you experience: severe allergic reaction symptoms (difficulty breathing, swelling of face/throat/tongue, severe skin rash with blistering); severe or bloody diarrhea during or up to several weeks after treatment (possible Clostridioides difficile infection); seizures or severe confusion; or signs of a severe skin reaction (widespread rash with fever and blistering).
Long-term treatment with cefotaxime (beyond 10–14 days) may be associated with a higher incidence of blood count abnormalities. Regular monitoring of complete blood count is recommended during prolonged therapy. Liver and renal function should also be monitored at regular intervals, particularly in patients receiving high doses or those with pre-existing organ impairment.
If you notice any side effects not listed here, or if any of the listed side effects become serious or bothersome, inform your healthcare team. Reporting suspected adverse reactions after authorization of the medicinal product is important for ongoing surveillance of its benefit-risk profile.
How Should You Store Cefotaxim MIP?
Proper storage of Cefotaxim MIP is essential to maintain the stability and effectiveness of the medication. The powder for injection/infusion should be stored in the original packaging to protect from light. The storage conditions differ between the unopened vial and the reconstituted solution.
- Unopened vials: Store below 25°C (77°F). Protect from light. Do not freeze. Keep out of the reach and sight of children.
- Reconstituted solution for injection: Chemical and physical in-use stability has been demonstrated for up to 12 hours at room temperature (up to 25°C) or up to 24 hours when refrigerated at 2–8°C. From a microbiological point of view, the reconstituted product should be used immediately.
- Diluted infusion solution: The diluted solution in 0.9% sodium chloride or 5% glucose should be used within 12 hours at room temperature or 24 hours if refrigerated. Do not use if the solution is cloudy or contains visible particles.
- Color change: Freshly reconstituted cefotaxime solutions range from pale yellow to light amber. A deepening of color does not necessarily indicate loss of potency, but solutions that have become dark yellow or brown should not be used.
Do not use Cefotaxim MIP after the expiry date stated on the label and carton. The expiry date refers to the last day of that month. Any unused medicinal product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste, typically through a hospital pharmacy or designated collection point.
What Does Cefotaxim MIP Contain?
Cefotaxim MIP contains a single active substance with a well-characterized chemical composition:
- Active ingredient: Cefotaxime sodium, equivalent to 1 g of cefotaxime per vial. Cefotaxime sodium is the sodium salt form of cefotaxime, which improves the water solubility of the compound and allows it to be prepared as a solution for injection.
- Excipients: The powder itself contains no additional excipients. Cefotaxime sodium is the sole component of the lyophilized (freeze-dried) powder.
- Sodium content: Each 1 g vial contains approximately 2.09 mmol (approximately 48.2 mg) of sodium. This is relevant for patients on sodium-restricted diets and should be taken into account when calculating total sodium intake, particularly when high doses are administered.
The reconstitution diluent is not included in the product and must be supplied separately. Acceptable diluents include Water for Injections (for IV or IM injection), 0.9% sodium chloride solution (for IV injection or infusion), 5% glucose solution (for IV infusion), and 1% lidocaine hydrochloride solution (for IM injection only, to reduce injection pain). The choice of diluent depends on the intended route of administration.
From a chemical perspective, cefotaxime is (6R,7R)-3-[(acetyloxy)methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Its molecular formula is C16H17N5O7S2, and its molecular weight is approximately 455.5 g/mol (477.4 g/mol for the sodium salt). The beta-lactam ring and the aminothiazolyl-oxyimino side chain are critical structural features responsible for its antibacterial activity and beta-lactamase stability, respectively.
Cefotaxime is metabolized in the body to desacetylcefotaxime, its primary metabolite, which retains antibacterial activity (approximately 10% of the activity of the parent compound against most organisms). This active metabolite contributes to the overall therapeutic effect, particularly for organisms with lower susceptibility, and may act synergistically with cefotaxime itself against certain bacteria.
Frequently Asked Questions
Cefotaxime and ceftriaxone are both third-generation cephalosporin antibiotics with similar spectra of activity against Gram-positive and Gram-negative bacteria. The main differences are pharmacokinetic: ceftriaxone has a much longer half-life (approximately 6–9 hours versus 1 hour for cefotaxime), allowing once-daily dosing, while cefotaxime requires multiple daily doses. Cefotaxime is generally preferred in neonates because ceftriaxone can displace bilirubin from albumin binding sites, increasing the risk of kernicterus. Ceftriaxone is also associated with biliary sludge and pseudolithiasis, which is not seen with cefotaxime. Both antibiotics penetrate the CSF well when meninges are inflamed.
Yes, cefotaxime is one of the preferred cephalosporins for use in neonates. Unlike ceftriaxone, it does not displace bilirubin from albumin and does not cause biliary sludge, making it safer in the neonatal period. It is commonly used for neonatal sepsis and meningitis. Doses are adjusted based on gestational age and postnatal age, typically 50–200 mg/kg/day divided into 2–3 doses. Premature neonates require lower doses due to their immature renal function and longer drug elimination times.
No, Cefotaxim MIP (cefotaxime) does not have clinically useful activity against methicillin-resistant Staphylococcus aureus (MRSA). MRSA possesses an altered penicillin-binding protein (PBP2a, encoded by the mecA gene) with low affinity for virtually all beta-lactam antibiotics, including cefotaxime. If MRSA infection is suspected or confirmed, alternative antibiotics such as vancomycin, linezolid, or daptomycin should be used. Your doctor will choose the most appropriate antibiotic based on culture and sensitivity results.
Cefotaxime begins killing bacteria almost immediately after administration, as it reaches effective concentrations in the blood within minutes of intravenous injection. Clinical improvement, however, typically takes 24–72 hours depending on the type and severity of infection. For bloodstream infections and pneumonia, fever may start to subside within 48–72 hours. For meningitis, clinical improvement usually begins within 24–48 hours. It is crucial to complete the full prescribed course even if you feel better, as stopping treatment early can lead to treatment failure and the development of antibiotic-resistant bacteria.
Yes, like virtually all antibiotics, cefotaxime can disrupt the normal intestinal flora and allow overgrowth of Clostridioides difficile (formerly Clostridium difficile), leading to C. difficile-associated diarrhea (CDAD) or pseudomembranous colitis. Third-generation cephalosporins are considered among the antibiotic classes with a higher risk for CDAD. Symptoms may occur during treatment or up to several weeks after antibiotic therapy has ended. Mild cases may resolve after stopping the antibiotic, but moderate to severe cases require specific treatment with oral vancomycin or fidaxomicin. If you develop persistent diarrhea (especially watery or bloody) during or after treatment, inform your doctor immediately.
Cefotaxime is partially removed by hemodialysis. The extent of removal varies depending on the dialysis parameters (membrane type, blood flow rate, dialysis duration). As a general rule, a supplementary dose of cefotaxime should be administered after each hemodialysis session to ensure adequate therapeutic levels. Peritoneal dialysis removes cefotaxime less effectively than hemodialysis. Patients on continuous renal replacement therapy (CRRT) may require dose adjustment based on the specific CRRT modality and effluent flow rate. Consult your nephrologist and infectious disease specialist for individualized dosing recommendations.
References
- European Medicines Agency (EMA). Cefotaxime – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed January 2026.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023. Available at: www.who.int.
- Infectious Diseases Society of America (IDSA). Practice Guidelines for the Management of Bacterial Meningitis. Clinical Infectious Diseases. 2024.
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 14.0, 2025. Available at: www.eucast.org.
- British National Formulary (BNF). Cefotaxime Monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk. Accessed January 2026.
- Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia: Elsevier; 2020.
- Brogden RN, Spencer CM. Cefotaxime: A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections. Drugs. 1997;53(3):483–510.
- Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clinical Infectious Diseases. 2004;39(9):1267–1284.
- McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018;66(7):e1–e48.
- WHO AWaRe (Access, Watch, Reserve) Classification of Antibiotics for Evaluation and Monitoring of Use, 2023. Geneva: World Health Organization; 2023.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Infectious Diseases and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, IDSA, and EUCAST guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses, and international clinical practice guidelines
Last Reviewed
– Next review scheduled within 12 months
All content is independently produced without pharmaceutical industry funding or influence. Our editorial team follows the GRADE evidence framework and adheres to international medical guidelines. For questions about our editorial process, visit our editorial standards page.